id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2025-N-2976-0003,FDA,FDA-2025-N-2976,Improving Anaphylaxis Outcomes: Approaches for Enhancing Access to Epinephrine; Public Workshop; Request for Comments,Notice,Request for Comments,2025-11-24T05:00:00Z,2025,11,2025-11-24T05:00:00Z,2026-01-17T04:59:59Z,2026-01-17T13:20:26Z,2025-20658,0,0,09000064b909369d
FDA-2025-N-2976-0001,FDA,FDA-2025-N-2976,Submission of Comments,Other,Request,2025-11-04T05:00:00Z,2025,11,2025-11-04T05:00:00Z,2026-01-17T04:59:59Z,2026-01-17T13:19:28Z,,0,0,09000064b9068efc